Medicure (CVE:MPH) Sets New 52-Week High – Should You Buy?

Medicure Inc. (CVE:MPH)’s share price hit a new 52-week high during mid-day trading on Monday. The company traded as high as C$4.39 and last traded at C$4.30, with a volume of 5,901 shares traded. The stock had previously closed at C$4.25.

Medicure Stock Performance

The firm has a market capitalization of C$44.87 million, a PE ratio of -5.97 and a beta of 0.98. The company has a debt-to-equity ratio of 6.02, a current ratio of 0.97 and a quick ratio of 1.28. The firm has a fifty day moving average price of C$2.43 and a 200 day moving average price of C$1.61.

About Medicure

Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.